Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Rhea-AI Summary
Dyadic Applied BioSolutions (NASDAQ: DYAI) and Proliant Health & Biologicals announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic’s filamentous fungal expression technology on Feb 17, 2026.
Under the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales. Proliant plans an expanded AlbuFree™ line later in 2026, including a formulation targeted for the cell culture market. Dyadic said the launch advances its strategy to convert licensed programs into recurring revenue and validates its microbial platform for scalable, animal-free protein production.
Positive
- Commercial launch of AlbuFree™ DX (recombinant human albumin)
- Profit-share agreement established with Proliant for commercial sales
- Planned product expansion with a cell culture formulation expected later in 2026
Negative
- No financial terms disclosed for the profit-share or expected revenue
- Revenue dependent on Proliant commercial execution and distribution performance
Market Reality Check
Peers on Argus
DYAI was up 0.61% pre-news while close peers showed mixed moves, from -20.62% (LSB) to +8.82% (CASI). Momentum scanner only flagged SNTI, which was down, suggesting DYAI’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Strategic collaboration | Positive | -1.4% | Expanded Fermbox Bio collaboration for commercial-scale manufacture and co-commercialization. |
| Dec 15 | Commercial partnership | Positive | -9.3% | Opes Diagnostics agreement to distribute Dyadic recombinant growth factors and media proteins. |
| Dec 01 | Development deal | Positive | -1.8% | BRIG BIO agreement to develop animal-free bovine alpha-lactalbumin for nutrition markets. |
| Nov 12 | Quarterly earnings | Negative | -3.7% | Q3 2025 report with lower revenue and wider net loss during commercial pivot. |
| Nov 10 | Technology license | Positive | +6.9% | CRISPR/Cas9 license from ERS Genomics to enhance genetic engineering capabilities. |
Positive strategic and partnership announcements have often seen negative or muted next-day reactions, while clearly financial or platform-expansion news has aligned more with price moves.
Over the last few months, Dyadic has focused on commercializing its microbial platforms through partnerships and financings. On Nov 10, 2025, a CRISPR/Cas9 license drove an aligned positive move of +6.91%. Subsequent earnings on Nov 12, 2025 showed revenue pressure and a wider loss, with the stock falling 3.69%. Multiple commercialization and collaboration deals in late 2025 (Opes Diagnostics, BRIG BIO, Fermbox Bio) were followed by negative price reactions, indicating the market has not consistently rewarded partnership headlines alone. Today’s commercial launch builds directly on that commercialization narrative.
Market Pulse Summary
This announcement marks Dyadic’s first major commercial step with AlbuFree DX, a recombinant human albumin product produced on its microbial platform. It extends a series of collaborations and commercialization efforts across cell culture and life science markets. Investors may track adoption of this product line, the timing of additional AlbuFree variants, and how these efforts translate into reported revenue and progress toward stabilizing the company’s broader financial profile.
Key Terms
recombinant human albumin medical
cell culture media medical
recombinant proteins medical
AI-generated analysis. Not financial advice.
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic’s proprietary filamentous fungal expression technology.
The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin products.
“This launch is a clear validation of Dyadic’s technology and our commercialization strategy,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “Recombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.”
Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFree™ DX marks the first major commercial step in Dyadic’s growing portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams.
“Proliant has decades of experience producing albumin at global scale and supplying customers through an established worldwide distribution network,” said Chris Detzel, President and Chief Executive Officer of Proliant Health & Biologicals. “AlbuFree™ DX builds on that foundation by adding a high-quality, animal-free recombinant human albumin to our diagnostic market portfolio, allowing us to meet growing customer demand while maintaining the consistency, reliability, and scale our customers expect. Further expansion of the AlbuFree™ line is expected later this year with the next version specifically formulated for the cell culture market.”
“This milestone demonstrates that Dyadic’s microbial platforms are well-suited for products that can be efficiently integrated into existing manufacturing, quality, and commercial infrastructures,” Hazelton added. “We believe this further reinforces the applicability of Dyadic’s technology for scalable commercialization in large, established markets.”
Dyadic continues to advance additional recombinant proteins for cell culture, life science, nutrition, and industrial applications through a combination of internal programs and strategic partnerships.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com
About Proliant Health & Biologicals
Proliant Health & Biologicals is a global leader in the production of purified bovine and recombinant proteins, serving life science, diagnostic, nutrition, and medical markets worldwide. With decades of manufacturing expertise, vertically integrated operations, and a global network of distributors and customers, Proliant is recognized for its scale, quality, and reliability in albumin and specialty protein supply. For more information about AlbuFree™ DX and Proliant please visit phb1.com
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.
Media contacts:
Dyadic Applied BioSolutions:
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
Proliant Health and Biologicals:
Alexis Voss
Email: Alexis.voss@phb1.com
FAQ
What is AlbuFree DX and why did Dyadic (DYAI) launch it on Feb 17, 2026?
How will Dyadic (DYAI) earn from Proliant’s commercial sales of AlbuFree DX?
What markets does AlbuFree DX target and what is the next product step for DYAI?
Does Dyadic (DYAI) disclose financial impact or revenue guidance from the AlbuFree DX launch?
Why is the AlbuFree DX launch significant for Dyadic (DYAI)’s commercialization strategy?
